Nobel Prize-winning discoveries launched their mission to change lives by changing the course of blood cancer.
As Geron advances towards FDA approval (with their first drug, RYTELO), their website needed to be a flexible, editorial driven experience. Research began with Geron employees behind the creation of RYTELO, as well as company leadership, manufacturing, and communications executive to plan, and shape the content.
User experience was focused on supporting ongoing industry news, as well as varying levels of investor, and media attention. Geron's brand was enhanced with a series of custom gradients, and infographics to emphasize their bold nature, and indicate milestones on their journey to commercialization.
Created in partnership with the outstanding account, and development teams at Syneos Health, and brand designers at Addison Witney.
FDA approved RYTELO on June 6, 2024
Animation was designed to explain how Telomerase operates in the bloodstream. The final video was used to showcase these advancements to investors, and the media, as well as event experiences. R&D Pipeline was reimagined to smoothly flow between the desktop, tablets, and mobile.
